Barriers to Access

Coverage & eligibility

Commercial insurance: Many plans still exclude anti‑obesity medications or restrict coverage to narrow formularies. Approvals usually require BMI and comorbidity criteria, documentation of prior lifestyle interventions, and periodic re‑authorization.
Medicare: Beginning July 1, 2026, eligible Medicare Part D beneficiaries can access certain GLP-1 medications for weight management through the CMS Medicare GLP-1 Bridge, with a $50 monthly copay. The demonstration is scheduled to continue through December 31, 2027.
Bridge-covered medications: The Medicare GLP-1 Bridge currently includes Foundayo®, Wegovy® injection and tablets, and Zepbound® KwikPen®. The single-dose Zepbound vial and single-dose pen are not included.
Medicaid: Coverage is state‑specific, often with strict prior‑authorization rules; some states exclude weight‑loss indications entirely.
Step therapy & quantity limits: Many payers require trying older agents first and cap monthly quantities or dose escalations, slowing titration.
BALANCE Model: CMS is implementing the voluntary BALANCE Model in participating state Medicaid programs to expand access to select GLP-1 medications and lifestyle interventions. The Medicare Part D portion of BALANCE will not launch in 2027 as originally planned. Eligible Medicare Part D beneficiaries can instead access qualifying GLP-1 medications through the separate Medicare GLP-1 Bridge through December 31, 2027, while CMS evaluates potential future implementation of BALANCE in Part D.

Cost & affordability

Cash prices are often unaffordable when coverage is excluded. Even with coverage, coinsurance and deductibles can be high. Manufacturer savings cards usually don’t apply to Medicare/Medicaid and may be limited by copay accumulator policies. For eligible Medicare Part D beneficiaries, the Medicare GLP-1 Bridge provides certain GLP-1 medications for weight management at a $50 monthly copay through December 31, 2027. Because the Bridge operates outside the regular Part D benefit, the $50 copay does not count toward the Part D deductible or annual out-of-pocket costs.

Utilization management (paperwork friction)

Prior authorization (PA): Payers commonly require baseline weight/BMI, ICD‑10 codes, comorbidities, prior therapies, and a titration plan. Renewals may demand proof of minimum % weight loss within 3–6 months or therapy is stopped.
Appeals: Initial denials are common; appeals need detailed clinical rationale, chart notes, and sometimes peer‑to‑peer review.
Medicare GLP-1 Bridge prior authorization: To access an eligible medication through the Medicare GLP-1 Bridge, a medical provider must submit a prescription and a separate prior authorization request. CMS uses a central processor to manage prior authorization and claims. Once approved, the authorization generally remains valid through December 31, 2027; a new prior authorization is required if the beneficiary switches to a different covered GLP-1 medication.

Pharmacy & logistics

Restricted distribution/specialty pharmacy: Plans may require a particular specialty pharmacy, causing delays when local stock is limited.
Storage & device handling: Some injectable GLP-1 medicines require refrigeration or specific storage conditions, and patients may also need training on how to use injection devices safely. These requirements can create additional barriers for some patients.
Strength availability: Specific pen strengths may be out of stock locally, complicating safe dose escalation.

Telehealth‑specific hurdles

Some platforms are out of network, charge separate membership fees, or don’t complete PAs—leaving patients to navigate approvals alone. Delays can occur when the dispensing pharmacy isn’t disclosed or when shipping is the only option. FDA has also taken enforcement action against telehealth companies that used false or misleading marketing for compounded GLP-1 products. Patients should verify the prescriber, pharmacy, and medication source before purchasing GLP-1 medicines online.

Information & safety

Counterfeit, illegally marketed, and unapproved GLP-1 products are promoted online. Compounded GLP-1 medicines are not FDA-approved and should generally be used only when a patient’s medical needs cannot be met by an available FDA-approved drug. Patients should obtain prescription medicines from a state-licensed pharmacy and avoid unverified online sellers.

Equity considerations

Language access, broadband, transportation, and provider availability all affect the ability to obtain, store, and safely use GLP-1 medicines—disproportionately impacting rural and under-resourced communities.

What helps

Ask your clinician to include diagnosis, comorbidities, prior therapies, and a titration plan in the initial PA.
If you may qualify for the Medicare GLP-1 Bridge, ask your clinician whether they can submit the required CMS prior authorization for an eligible medication.
Request copies of denial letters and pursue appeals; many are approved on reconsideration with additional evidence.
Explore patient‑assistance or foundation support where eligible.
Use a state‑licensed U.S. pharmacy and avoid “too good to be true” offers to reduce safety risks

Take Action

Demand safe & affordable access

Take Action

Report a Scam

Submit suspicious product

Report a Scam

Share Your Story

Join our digital storytelling series

Share Your Story

Frequently Asked Questions

Timeline: The Treat & Reduce Obesity Act (TROA)

Counterfeit or illegally marketed weight-loss drugs may contain the wrong ingredient, an incorrect amount of medicine, or harmful contaminants. Products from unverified sources may also have misleading labels, unsafe storage conditions, or unclear dosing instructions. Use prescription GLP-1 medicines only under the care of a licensed health care professional and obtain them from a licensed pharmacy.

FDA-approved GLP-1 medicines have been reviewed by the FDA for safety, effectiveness, quality, and manufacturing standards. Compounded GLP-1 medicines are not FDA-approved and are not reviewed by the FDA before they are marketed for safety, effectiveness, or quality. Compounded medicines may be appropriate for certain patients with a specific medical need that cannot be met by an available FDA-approved drug.

Ask why a compounded medicine is being recommended and whether an FDA-approved option can meet your medical needs. Compounded drugs can serve an important medical need for some patients, but they are not FDA-approved. If a compounded GLP-1 is prescribed, make sure it is filled by a properly licensed pharmacy and ask about the ingredients, dose, storage, and how to use it safely.

Avoid buying prescription GLP-1 medicines from social media sellers or websites that cannot be verified as legitimate pharmacies. Products from unlicensed or unverified sellers may be counterfeit, contaminated, improperly stored, or contain the wrong ingredients or dose. Get a prescription from a licensed health care professional and fill it through a state-licensed pharmacy.

Goal:

Expand Medicare to cover FDA-approved anti-obesity medications and allow more providers (NPs, PAs, RDNs, etc.) to deliver intensive behavioral therapy (IBT).

2013 (113th Congress):

First introduced — H.R. 2415 / S. 1184

2015 (114th):

Reintroduced — H.R. 2404 / S. 1509

2017 (115th):

Reintroduced — H.R. 1953 / S. 830

2019 (116th):

Reintroduced — H.R. 1530 / S. 595

2021 (117th):

Reintroduced — H.R. 1577 / S. 596

2023 (118th):

Reintroduced — H.R. 4818

2025 (119th, current):

Reintroduced — S. 1973 (June 5) and H.R. 4231 (June 27), with bipartisan support

Impact if passed:

Medicare patients could finally access GLP-1s and other obesity drugs through Part D.

Broader provider base could deliver behavioral therapy for weight management.